tetano
Editor, Senior Moderator
Int J Hematol
. 2022 Apr 15.
doi: 10.1007/s12185-022-03325-9. Online ahead of print.
Antibody response to COVID-19 vaccine in 130 recipients of hematopoietic stem cell transplantation
Takafumi Tsushima[SUP] 1 [/SUP], Toshiki Terao[SUP] 1 [/SUP], Kentaro Narita[SUP] 1 [/SUP], Ami Fukumoto[SUP] 1 [/SUP], Daisuke Ikeda[SUP] 1 [/SUP], Yuya Kamura[SUP] 1 [/SUP], Ayumi Kuzume[SUP] 1 [/SUP], Rikako Tabata[SUP] 1 [/SUP], Daisuke Miura[SUP] 1 [/SUP], Masami Takeuchi[SUP] 1 [/SUP], Kosei Matsue[SUP] 2 [/SUP]
Affiliations
Abstract
We evaluated anti-spike protein antibody (anti-S) production in 130 hematopoietic stem cell transplant (HSCT) recipients who received the coronavirus disease-2019 vaccine. Sixty-five received allo-HSCT and 65 received auto-HSCT. Disease-specific treatments were being administered to 43.1% of allo-HSCT and 69.2% of auto-HSCT patients. Seropositivity was observed in 87.7% of allo-HSCT and 89.2% in auto-HSCT patients. Anti-S antibody production was significantly impaired in auto-HSCT patients compared with controls (178U/mL [0.4-4990.0] vs. 669 U/mL [40.3-4377.0], p < 0.001), but not in allo-HSCT patients (900 U/mL [0.4-12,893.0] vs. 860 U/mL [40.3-8988.0], P = 0.659). Clinically relevant anti-S antibody levels (> 264 U/mL) were achieved in 59.2% of patients (76.9% in allo-HSCT and 41.5% in auto-HSCT). The main factors influencing the protective level of the antibody response were the CD19 + cell count and serum immunoglobulin G levels, and these were significant in both allo-HSCT and auto-HSCT patients. Other factors included time since HSCT, complete remission status, use of immunosuppressive drugs, and levels of lymphocyte subsets including CD4, CD8 and CD56 positive cells, but these were only significant in allo-HSCT patients. Allo-HSCT patients had a relatively favorable antibody response, while auto-HSCT patients had poorer results.
Keywords: Allogeneic HSCT; Antibody; Autologous HSCT; COVID-19 vaccine.
. 2022 Apr 15.
doi: 10.1007/s12185-022-03325-9. Online ahead of print.
Antibody response to COVID-19 vaccine in 130 recipients of hematopoietic stem cell transplantation
Takafumi Tsushima[SUP] 1 [/SUP], Toshiki Terao[SUP] 1 [/SUP], Kentaro Narita[SUP] 1 [/SUP], Ami Fukumoto[SUP] 1 [/SUP], Daisuke Ikeda[SUP] 1 [/SUP], Yuya Kamura[SUP] 1 [/SUP], Ayumi Kuzume[SUP] 1 [/SUP], Rikako Tabata[SUP] 1 [/SUP], Daisuke Miura[SUP] 1 [/SUP], Masami Takeuchi[SUP] 1 [/SUP], Kosei Matsue[SUP] 2 [/SUP]
Affiliations
- PMID: 35426579
- DOI: 10.1007/s12185-022-03325-9
Abstract
We evaluated anti-spike protein antibody (anti-S) production in 130 hematopoietic stem cell transplant (HSCT) recipients who received the coronavirus disease-2019 vaccine. Sixty-five received allo-HSCT and 65 received auto-HSCT. Disease-specific treatments were being administered to 43.1% of allo-HSCT and 69.2% of auto-HSCT patients. Seropositivity was observed in 87.7% of allo-HSCT and 89.2% in auto-HSCT patients. Anti-S antibody production was significantly impaired in auto-HSCT patients compared with controls (178U/mL [0.4-4990.0] vs. 669 U/mL [40.3-4377.0], p < 0.001), but not in allo-HSCT patients (900 U/mL [0.4-12,893.0] vs. 860 U/mL [40.3-8988.0], P = 0.659). Clinically relevant anti-S antibody levels (> 264 U/mL) were achieved in 59.2% of patients (76.9% in allo-HSCT and 41.5% in auto-HSCT). The main factors influencing the protective level of the antibody response were the CD19 + cell count and serum immunoglobulin G levels, and these were significant in both allo-HSCT and auto-HSCT patients. Other factors included time since HSCT, complete remission status, use of immunosuppressive drugs, and levels of lymphocyte subsets including CD4, CD8 and CD56 positive cells, but these were only significant in allo-HSCT patients. Allo-HSCT patients had a relatively favorable antibody response, while auto-HSCT patients had poorer results.
Keywords: Allogeneic HSCT; Antibody; Autologous HSCT; COVID-19 vaccine.